70 Years of Advancing Pharmaceutical and Biopharmaceutical Manufacturing
## Contents

Celebrating 70 Years of Advancing Pharmaceutical and Biopharmaceutical Manufacturing  | 2
---|---
A Growing, Diverse Membership  | 3
Chair Message  | 4
Board of Directors  | 5
PDA Vision and Mission  | 6
President’s Message  | 7
People  | 8
Honor Award Winners  | 9
Advisory Boards & Committees  | 10
Membership Chapters & Chapter Leaders  | 11
Japanese 25th Anniversary and Awards  | 12
Education  | 13
Conferences/Workshops  | 15
Science  | 16
Regulatory  | 18
PDA Staff  | 19
Financials  | 20
PDA/FDA Joint Regulatory Conference 25th Anniversary  | 21

According to the Charter, PDA was formed to:

- Foster and advance, in the interest of public health, the art and science of parenteral therapy, and to preserve and improve the integrity and stability of the parenteral drug industry
- Provide and disseminate information relating to parenteral drugs and parenteral therapy
- Foster and encourage a spirit of friendly cooperation among its members and the medical and pharmaceutical professions
- Cultivate and maintain cooperative relations with governmental departments and agencies, medical and pharmaceutical organizations, and other branches of the drug and related industries; and to originate and participate in cooperative enterprises and undertakings with them
- Collect and disseminate, for the benefit of members, such business and scientific information as may be of value to them
- Sponsor research projects into matters of scientific and technical interest in the field of parenteral medication
- Review the labeling and advertising of its members in the light of current regulations and advances in medical science, and dispel uncertainty in such matters
- Promote higher standards in the production of parenteral drugs

Certainly, many of those goals define the work of PDA’s various volunteers 70 years later, but the original charter did not mention anything about a global industry or global challenges. That is because for its first 40 years, PDA was a U.S.-centric organization. That began changing in the 1990s, as the industry started down the road of rapid globalization with the freeing up of trade regulations around the world. PDA immediately rose to these many challenges faced by a globalizing industry. (invert this sentence with next sentence). The ramifications of rapidly expanding supply chains, marketplaces, labor forces and regulatory requirements continue to ripple through the industry and will do so for years to come.

These challenges drive PDA’s members to come together on a variety of activities to help the broader global industry. In just the last few years, PDA volunteer members have formed task forces to provide guidance on the topics directly related to a globalized industry: data integrity, post-approval changes, drug shortages, and quality metrics/culture. While PDA is the leader in providing technical information and training on sterile drug processing, our members’ efforts in these and other global areas make PDA a strong leader on many fronts that help drive continuous improvement in pharmaceutical/biopharmaceutical manufacturing.

Globalization is changing the demographics of PDA’s membership. Thirty years ago, nearly all PDA’s members were in the USA. Twenty years ago, PDA’s nascent international activities were concentrated in Europe and Japan. Today, PDA hosts four chapters in Europe, one in Israel, six in the Asia Pacific region, and began developing its first in South America in 2016.

It has been an amazing and highly successful 70 years for PDA. While many of its founding goals remain relevant, the globalized industry has changed PDA’s constituency and its members’ impact on the industry at large for the better.
A Growing, Diverse Membership

More than 10,000 members from industry, government, and academia at every stage of a career reside in 79 countries around the world. More than 2,500 of these global members support PDA’s initiatives as active volunteers.
It is appropriate that PDA was the first organization to receive a Johnson & Johnson Kilmer Award for leadership in the science of sterility assurance during our celebratory 70th anniversary year. Indeed, PDA’s members have been leaders in this important field since its founding. As PDA President Richard Johnson said upon accepting the award, PDA’s first meetings on sterility assurance were held before most of us were born!

Over the course of seventy years, PDA’s efforts to advance the science of sterility assurance and aseptic processing have touched upon numerous key industry developments. PDA led the charge to improve sterilization science—an effort that gave birth to PDA’s technical reports. Ensuring the promulgation of best practices in aseptic processing gave birth to PDA’s first laboratory course at the Training and Research Institute. When the U.S. FDA endeavored to provide industry guidance on aseptic processing, PDA was there to serve as both a check and a partner, helping the Agency craft a scientifically sound guidance. As biotech products increased in number and importance, PDA again stepped in and developed technical documents, courses and conferences on viral filtration and removal.

With an ever-growing and internationalizing membership, PDA’s activities naturally spread into other areas of importance, including supply chain security, prefilled syringes, combination products, quality systems and risk management, data integrity, cold chain shipping, cell and gene therapies, and many, many other areas.

In 2016, PDA launched major initiatives in manufacturing science, eliminating visual particulates, and post-approval changes regulations to help industry address the complicated and interconnected problems caused by aging facilities and processes and the regulatory hurdles that impede modernization. The Manufacturing Science and Operations Program was organized to highlight the ongoing focus PDA has on pharmaceutical and biopharmaceutical manufacturing.

PDA was proud to announce a significant initiative bringing together executives including CEOs and Executive Vice Presidents from biologic and pharmaceutical manufacturers with glass container and elastomeric closure suppliers. Their aspiration is through collective and collaborative continuous improvement projects to take today’s world-class injectable medicine manufacturing to the next level, preparing industry for the complex products and manufacturing processes of the future by eliminating visible particles from parenteral products. The Taskforce consists of multidisciplinary members from biologic and pharmaceutical manufacturers along with suppliers of glass container and elastomeric closures with over 1,000 years of experience. This initiative will focus on the entire supply chain from raw materials to finished product.

The PDA Post-Approval Change Innovation for Access to Medicines (PAC iAM) is a program intent on reducing the hurdles to pharmaceutical manufacturing innovation. The group is tasked to educate the industry and regulators of the current challenges, develop science-based solutions, and encourage international regulatory cooperation.

PDA’s 70th Anniversary appropriately saw PDA’s members once again working to assure sound regulatory guidance on sterile drug manufacturing, but this time the focus was pending changes to the European Medicine Agency’s GMP guidance, Annex 1. PDA sponsored four workshops on the topic to generate information on current best practices. PDA published a two-part Points to Consider for Aseptic Processing prior to the workshops. Earlier in the year, PDA also published a first-of-its kind comparison of sterile processing GMPs electronic book.

Many things about PDA have changed in 70 years, yet its role as a leader in pharmaceutical manufacturing and sterilization processes remains as strong as ever.
Board of Directors

Chair
Martin VonTrieste

Chair-Elect
Rebecca Devine, PhD
Regulatory Consultant

Secretary
Jette Christensen
Novo Nordisk

Treasurer
Michael Szadowski
Baxter Healthcare

Immediate Past Chair
Harold Baseman
VabSource

Masahiro Akimoto
Otsuka Pharmaceutical Factory, Inc.

Deborah M. Autor
Mylan

Joyce Bloomfield
Novartis

Ursula Busse, PhD
Novartis

Veronique Davoust
Pfizer

Emma Remmarine
Genentech/Roche

Stephan Römninger
Aptin

Anil Sawant
Merck

Susan Schiepp
Regulatory Compliance Associates

Melissa Seymour
Biogen

Glenn Wright
Eli Lilly and Company
To advance pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients.

**Science Based:** Science is the foundation of our organization. We utilize a scientific approach to meet challenges and continuously improve. It is not subjective or emotional, but rather a logical, open, rational and transparent process.

**Integrity:** We are relentless in applying the highest ethical standards to our products, services and actions. We will never compromise ethics. We will be known for living to the highest forms and standards of ethical behavior. We will honor our commitments.

**Inclusion:** We work together to create a culture of inclusion built on trust, respect and dignity for all. We contribute to the advancement of pharmaceutical/biopharmaceutical operations by building partnerships with professionals in academia, industry and regulatory bodies to better serve patients.

To maximize product quality, availability, and value by connecting people, science, and regulation within the pharmaceutical and biopharmaceutical community so that PDA is:

- The preferred choice for professionals who seek specialized, innovative skills and knowledge enhancing their professional development.
- The premier educational partner for professionals in academia, industry and government for the advancement of manufacturing, quality and regulatory science.
- An organization that aligns its practices and resources in support of its core values of science based, integrity, and inclusion.
President’s Message

Our Mission remains steadfast: *To advance pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients.* PDA continues our leadership in pharmaceutical and biopharmaceutical manufacturing, and we are the benchmark that others measure themselves against. 2016 was a busy, challenging, and ultimately successful year for PDA where together we continued to Connect People, Science and Regulation®. Our focus remained providing service to our members and the pharmaceutical community. Together, we exemplified our values: being Science Based; demonstrating Integrity; and promoting Inclusion.

PEOPLE
Membership in PDA continued to grow around the world, with more than 41% of our members coming from outside North America. This global reach included establishment of a new chapter in Brazil.

In 2016 we had a record number of attendees at our conferences and our education programs, which included delivering training to more than 350 health authority members. We continued to have industry leading conferences, including our 65th Annual Meeting in San Antonio, our 25th PDA Joint Regulatory Conference, and our world leading Universe of Prefilled Syringes meeting. 2016 saw the launch of our 1st PDA Europe Annual meeting, and our focus on Aseptic Processing and Data Integrity was reflected in 4 global workshops for each topic.

SCIENCE
Science has always been a cornerstone of PDA, and is a core value. In 2016 this was evidenced by the continued excellence of our technical volunteer activities, including the publication of four (4) Technical Reports (covering topics ranging from Prefilled Syringe User Requirements to Application of Phase Appropriate Quality System and cGMP to the Development of Therapeutic Drug Substance), four (4) “Points to Consider” (on Data Integrity, Post Approval Changes, Aging Facilities and Aseptic Processing), and three (3) Surveys, and two (2) PDA books.

REGULATION
Ours is a highly regulated industry, and PDA continued to seek ways to inform our members of the latest regulatory expectations. We worked with Heath Authorities to provide timely, technical and meaningful science-based input on draft guidance, including formal written comments on more than 15 documents. In a spirit of collaboration and mutual interest, we worked with regulators on most of our conferences, most notably the 25th Annual PDA/FDA Joint Regulatory Conference, and the highly successful ICH Q7 collaboration with PIC/S. PDA also continued our contribution to commenting on sixteen (16) draft regulatory guidances from EMA, FDA, WHO, MHRA and USP.

LEADERSHIP & MANAGEMENT
PDA as an organization must stand on a firm foundation, and as stewards of your Association, we continue to develop tools and resources to fulfill our mission, while maintaining a strong financial base. We relocated our Global Headquarters in Bethesda, MD to larger facilities, and expanded our Training and Research Institute to offer more capability to our students. All of our Education program had a record year, and we continued our 7th consecutive year of positive revenue.

In the following pages there will be much more detail about these activities. Let me take this opportunity to thank all of the many volunteers and members who made these things happen. Without you, these accomplishments would not be possible. As always, remember, this is your association. Your input is valued and appreciated.
PDA is driven by the people who support it. In 2016, the association had **2,500 volunteers** out of a membership of more than 10,000 professionals.

**Member Satisfaction**

- **86%** of members are somewhat satisfied or very satisfied with their PDA membership
- **88%** believe the value of membership is equal to or greater than the cost of dues
- **49%** of PDA’s members are classified as Promoters

Among the various member benefits is a free subscription to the *PDA Letter*.
Honor Award winners are those members whose contributions have most helped PDA fulfill its mission. Among the thousands of volunteers who work with PDA, these honored members are recognized for exceptional dedication and years of service at the PDA Awards Dinner during the Annual Meeting. PDA congratulates and thanks the following recipients.

**Honorary Membership**
This is PDA’s most prestigious award, conferring lifetime membership benefits to the recipient. The award has traditionally been given in recognition of long service significant in nature to PDA and requires unanimous approval from the Board of Directors.

**Georg Roessling, PhD**

**Gordon Personeus Award**
Presented in memory of the late Gordon Personeus, a past PDA President and long-time volunteer, this award honors a PDA member other than a Board member for long-term acts or contributions that are noteworthy or of special importance.

**Art Vellutato**

**Frederick J. Carleton Award**
This award is presented as a tribute to lifetime contributor, past President, past Executive Director and Honorary Member Frederick J. Carleton, and designated for past or present Board members.

**Junko Sasaki**  **Anders Vinther, PhD**

**Edward Smith Packaging Science Award**
In honor of long-time volunteer Edward Smith, who led PDA’s packaging science activities, this award is given in recognition of extraordinary contributions to PDA and the packaging science.

**Roger Asselta**

**Martin VanTrieste Pharmaceutical Science Award**
Established in honor of long-time contributor and Chair-Elect Martin VanTrieste, this award is given annually for outstanding contributions to the advancement of pharmaceutical science.

**Kurt Borson, PhD**  **Hannelore Wilkommen, PhD**

**Distinguished Service Award**
This award is given in recognition of special acts, contributions or services that have promoted the success and strength of PDA.

**Ed Balkovic, PhD**  **Ghada Haddad**  **Kamikukita, PhD**  **Narwal**  **Morton Munk**

**PDA Europe Service Appreciation Award**
This award is presented annually for special acts, contributions, or services that have contributed to the success and strength of PDA's European activities.

**Brigitte Reutter-Haerle**

**Service Appreciation Award**
The Service Appreciation Award is presented annually for special acts, contributions, or services.

<table>
<thead>
<tr>
<th>Shannon Bellino</th>
<th>Melissa Morandi</th>
<th>David Spaulding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gaetano</td>
<td>Jonathan Morse</td>
<td>Brian Underhill</td>
</tr>
<tr>
<td>Fiorentino</td>
<td>Susan Schniepp</td>
<td>Michael VanDerWerf</td>
</tr>
<tr>
<td>Beth</td>
<td>John Shabushnig, PhD</td>
<td>Glenn Wright</td>
</tr>
<tr>
<td>Kirschenheiter</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**James P. Agalloco Award**
The James P. Agalloco Award is presented annually to the PDA faculty member who exemplifies outstanding performance in education. The award is named for James P. Agalloco, in honor of his work in developing the PDA Education program.

**John Ludwig, PhD**

**Michael S. Korczynski Award**
Established in recognition of contributions made toward the development of PDA’s international activities by Michael S. Korczynski, PhD.

**Gabriele Gori**

**Frederick D. Simon Award**
The Frederick D. Simon Award is presented annually for the best paper published in the *PDA Journal of Pharmaceutical Science and Technology*. This award is named in honor of the late Frederick D. Simon, a former PDA Director of Scientific Affairs. This year’s award went to six recipients for their contribution to the article, “Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying—the Road to Manufacturing Scale,” which was published in the January/February 2015 issue of the PDA Journal.

**Patricia Cash, PhD**  **Maryam Mazaroti**  **Stephan Krause, PhD**  **Derek Murphy**  **Sophia Levitskaya-Seaman, PhD**  **Roja Narwal**

**Distinguished Editor/Author Award**
This award recognizes the author or editor selected by PDA members for their contribution to PDA’s technical books. This year’s award went to the editor of the book, Assuring Data Integrity for Life Sciences.

**Siegfried Schmitt, PhD**

**President’s Award**
This award recognizes a PDA staff member, other than senior staff, whose exemplary performance has contributed to PDA’s success during the previous year.

**Creixell Espilla-Gilart**  **Trevor Swan**
Advisory Boards & Committees
Membership Chapters & Chapter Leaders

**Canada**
Antonella Maggio, Harmonium International

**United States**
- **Capital Area**
  Allen Burgenson, Lonza Walkersville, Inc.
- **Delaware Valley**
  Jason Mattis, Janssen (Johnson & Johnson)
- **Metro**
  Leticia Quinones, Bristol-Myers Squibb
- **Midwest**
  Kenneth Paddock, Baxter Healthcare Corporation
- **Missouri Valley**
  Keith Koehler, Excite Pharma Services
- **Mountain States**
  Suzanne Mecalo, Commissioning Agents, Inc.
- **New England**
  Amnon Eylath, Karyopharm Therapeutics, Inc.
- **Southeast**
  Renee Morley, STERIS Corporation
- **Southern California**
  Randy George, Rescop Inc.
- **Texas**
  Greg Williams, Novartis Pharmaceuticals Corp.
- **West Coast**
  Steven Dawson, Genentech, Inc.

**Puerto Rico**
Myriam Sosa, Merck

**Brazil**
Leonidas Orjuela, Audisis Vale

**Canada**
Antonella Maggio, Harmonium International

**United States**
- **Capital Area**
  Allen Burgenson, Lonza Walkersville, Inc.
- **Delaware Valley**
  Jason Mattis, Janssen (Johnson & Johnson)
- **Metro**
  Leticia Quinones, Bristol-Myers Squibb
- **Midwest**
  Kenneth Paddock, Baxter Healthcare Corporation
- **Missouri Valley**
  Keith Koehler, Excite Pharma Services
- **Mountain States**
  Suzanne Mecalo, Commissioning Agents, Inc.
- **New England**
  Amnon Eylath, Karyopharm Therapeutics, Inc.
- **Southeast**
  Renee Morley, STERIS Corporation
- **Southern California**
  Randy George, Rescop Inc.
- **Texas**
  Greg Williams, Novartis Pharmaceuticals Corp.
- **West Coast**
  Steven Dawson, Genentech, Inc.

**United Kingdom**
Siegfried Schmitt, PAREXEL Consulting

**Ireland**
John Michael Morris, Health Products Regulatory Agency

**France**
Philippe Gomez, Sartorius Stedim

**Isreal**
Karin Baer, Teva Pharmaceutical Industries Limited

**India**
Sanjit Lamba, Eisai Co., Ltd.

**United Kingdom**
Siegfried Schmitt, PAREXEL Consulting

**Italy**
Angela Molaschi, Actavis Italy SPA

**Taiwan**
Yi-Yin Lu, Taiwan Parenteral Drug Association

**South Korea**
Woo-Hyun Paik, Korea Pharm. Tech. Education Center (KPTEC)

**Japan**
Hidehiro Daikoku, PDA Japan Chapter Secretariat

**Singapore**
Maureen Hertog, Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.

**Australia**
David Spaulding, SeerPharma
Japanese 25th Anniversary and Awards

The PDA Japan Chapter celebrated 25 years at its Annual Meeting, Nov. 29-30, in Tokyo. Awards were given to honor the hard work and dedication of volunteers who make PDA’s largest chapter so successful. PDA President Richard Johnson was on hand to honor the chapter and these noteworthy volunteers. Pictured below are the winners of the Kawamura Award, recognizing 25 years of active service to the Japan Chapter.

Katsuhide Terada, Kunio Kawamura, Yoshimi Urayama, Yoshito Heshimoto, Masayoshi Nishiyama, Richard Johnson, Harohiro Okuda, Tsutomu Kamikukita, Shinji Sugaya
Training has been a core function of PDA since 1946. In the early years, most of the training occurred through the dissemination of information and best practices through PDA’s publications and at conferences, but in the 1970’s, training courses were introduced.

At first, PDA offered an audio tape/slide series on aseptic products, aseptic filling, cleaning, documentation of process data, and a number of other important topics. By 1978, PDA’s education program expanded to include courses taught by subject matter experts like Dr. Irving Pflug on sterilization processes, temperature measurement in process validation by Dr. Clarence Kemper, particulate evaluation by Dr. Julius Knapp, and many, many more.

In 1997, PDA introduced its own hands-on Training and Research Institute, which began a major expansion at its Bethesda, Maryland home at the end of 2016. PDA Education—Where Excellence Begins—is now the premier place for pharmaceutical professionals worldwide to go to update their skills or learn new skills in aseptic processing, visual inspection, and a host of other topics relevant to their organizations and to advancing their careers.

### 2016 Lectures & Lab Courses

- **Airflow Visualization Techniques and Practices**
- **An Introduction to Visual Inspection**
- **An Introduction to Visual Inspection: A hands-on course | Berlin, Germany**
- **Application of Quality Risk Management to Non-Production Processes in the Pharmaceutical Quality System**
- **Application of a Quality Systems Approach to Pharmaceutical CGMPs**
- **Application of a Risk-Based Approach to Freeze-Drying Processes | Strasbourg, France**
- **Aseptic Processing Training Program**
- **Biopharmaceutical Manufacturing Under Regulatory Compliance: Process Strategies, CGMP Considerations and Facility Requirements**
- **Biosimilar CMC and Regulatory Challenges**
- **Charting and Trending of Environmental Monitoring Data: From Microbial Counts to Contamination Recovery Rates in Controlled Rooms**
- **Charting and Trending of Environmental Monitoring Data | Berlin, Germany**
- **Clean Room Design, Contamination Control, and Environmental Monitoring for Controlled Environments**
- **Cleaning and Disinfection | Berlin, Germany**
- **CMC Regulatory Compliance for Biopharmaceuticals | Rome, Italy**
- **CMC Regulatory Requirements in Drug Applications**
- **Container Closure Development | Venice, Italy**
- **Container Closure Integrity: Regulations, Test Methods, Application | Venice, Italy**
- **Contamination Control, Clean Room Design, and Environmental Monitoring for Controlled Environments**
- **Control, Validation and Monitoring of Biofilms in Water Systems | Berlin, Germany**
- **Design of Experiments (DoE) – The Basis of Validation | Berlin, Germany**
- **Development of a Freeze Drying Process | Strasbourg, France**
- **Development of a Pre-filled Syringe | Berlin, Germany**
- **Drug Delivery Combination Products | Venice, Italy**
- **Elastomers | Rome, Italy**
- **Endotoxin Attributes, Detection, Clinical Relevance and BET — Interference Resolution**
- **Environmental Control and Monitoring for Regulatory Compliance**
- **Essential Elements of Extractables and Leachables: From Material Selection to Final Report**
- **Establishing a Robust Relationship with Your Client/CMO**
- **Establishing and Implementing an Effective GMP Auditing Program**
- **Establishment of a Risk Based Environmental Monitoring Program**
- **Evaluation, Validation, and Implementation of Alternative and Rapid Microbiological Testing Methods**
- **Extractables and Leachables | Rome, Italy**
- **Extractables and Leachables | Venice, Italy**
- **FDA On-Site Training Series**
  - **Advanced Steam Sterilization**
  - **Basics of Steam Sterilization**
  - **Media Fills**
Filtration Processes in the Pharmaceutical and Biopharmaceutical Industry

Foreign Particulate Examination, Isolation, and Analysis (2 sessions)

Fundamentals of an Environmental Monitoring Program (2 sessions)

Fundamentals of Aseptic Processing

Fundamentals of Cleaning and Disinfectant Programs for Aseptic Manufacturing Facilities

Fundamentals of Lyophilization

From Gene to Product – Tailormade Strategies for High Level Expression of Biologicals | Rome, Italy

GMPs for Manufacturers of Sterile and/or Biotechnology Products

Going Deeper than Human Error: Finding More Specific Root Causes to Incidents involving people

Good Glass Handling Practices | Venice, Italy

Good Qualification Practice of Pharma Storage and Transportation Equipment | Amsterdam

How to find the right GMP for APIs | Berlin, Germany

Identification and Classification of Nonconformities in Molded and Tubular Glass Containers for Pharmaceutical Manufacturing

The Impact of cGMPs on Biomanufacturing Facility Design

Implementing Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

In-house Training Abbott Biologicals I | Olst

In-house Training Abbott Biologicals II | Olst

Investigating Microbial Data Deviations

Investigations - Best Practices

Isolator Technology

Knowledge Management Applied in Facilities & Engineering to Improve Manufacturing in Reliability

Management of Aseptic Processing

Managing the QC and R+D Laboratory in a GMP Compliant Manner

Microbiological Risk Assessment of a Pharmaceutical Manufacturing Process

The Metrics of Process Monitoring & Understanding the Risks of Variation | Rome, Italy

Outsourcing, Technology Transfer and CMO Client Relationships | Barcelona, Spain

Particle Identification in Parenterals | Berlin, Germany

Pharmaceutical Water Systems | Berlin, Germany

Praxis der Pharmazeutischen Gefriertrocknung | Osterode, Germany

Practical Application of GMP for Development of ATMPs | Berlin, Germany

Practical Aspects of Aseptic Processing

Practical Guide for Root Cause Investigations — Methodology & Tool Kit | Barcelona, Spain

Preparing for Regulatory Inspections for the FDA and EMA

Process Simulation Testing for Aseptically Filled Products

Virus Filtration | Berlin, Germany

Quality by Design for Biopharmaceuticals | Barcelona, Spain

Quality Metrics and Quality Culture | New England Chapter

Quality Metrics: Performance Indicators

Quality Risk Management for Facilities and Equipment

Quality Systems for Aseptic Processing

Recommended Practices for Manual Aseptic Processes

Rapid Microbiological Methods | Berlin, Germany

Risk Based Approach for Prevention and Management of Drug Shortages | Barcelona, Spain

Risk Based Qualification of Sterile Drug Product Manufacturing Systems

Risk Management in Technology Transfer | Barcelona, Spain

Role of the Quality Professional in the 21st Century

Root Cause Investigation for CAPA | Berlin, Germany

Single Use Systems for the Manufacturing of Parenteral Products

Secure Cold Chain | Amsterdam

Steam Sterilizers: Getting it Right from the Beginning

Sterile Pharmaceutical Dosage Forms: Basic Principles

Strategies for Reducing Human Error Nonconformances

Technology Transfer

Test Methods for Pre-filled Syringe Systems | Berlin, Germany

Track and Trace – Implementierung von Serialisierung, Fälschungssicherheit und Verifizierung für pharmazeutische Produkte | Leipzig, Germany

Introduction to Aseptic Processing Principles | Rome, Italy

Training Effectiveness: What’s Your Design Strategy?

Understanding and Addressing Technical, Quality, and Regulatory Challenges for Drug Delivery Combination Products - NEW

Understanding Product options, User Needs and Fill-Finish Requirements for Nested Format Syringes

Understanding Variation and the Metrics of Process Monitoring

Validation of Biotechnology-Related Cleaning Processes

Validation of Lyophilization

Validation of Moist Heat Sterilization Processes

Validation of Moist Heat Sterilization Processes: Cycle Design, Development, Validation and Ongoing Control

Trainees in the TRI lecture room
Conferences/Workshops

Over the last 70 years, there has been no better place for industry suppliers and manufacturers to network than PDA’s signature conferences. The Annual Meeting, the PDA/FDA Joint Regulatory Conference, the Universe of Prefilled Syringes, and the Pharmaceutical Microbiology Conference are four of PDA’s signature events that collectively draw thousands of participants and exhibitors each year, including healthy representation from regulators from around the world.

In 2016, PDA Europe held its first Annual Meeting and plans to build this event into another signature event that members and the industry can count on. The first event led with topics on leading-edge manufacturing technologies, Industry 4.0, and novel therapies.

2016 Conferences

11th Annual Global Conference on Pharmaceutical Microbiology | Arlington, VA
Annex 1 | Berlin, Germany
Annex 1 | Dublin, Ireland
Annex 1 Workshop | Arlington, VA
Annex 1 Workshop | San Diego, CA
Annual Meeting | San Antonio, TX
Annual Meeting | Berlin, Germany
ATMP | Berlin, Germany
Biosimilars Conference | Baltimore, MD
Cold/Supply Chain | Amsterdam, Netherlands
Critical Demands on Modern Pharmaceutical Packaging | Bern, Switzerland
Data Integrity | London, Great Britain
Data Integrity | Berlin, Germany
Data Integrity Workshop | San Diego, CA
Data Integrity Workshop | Washington, DC
Drug Delivery Combination Products Workshop | Huntington Beach, CA
Freeze Drying | Strasbourg, France
IG PFD | Berlin, Germany
IG VI | Berlin, Germany
IG UPS | Venice, Italy
Iran Meeting | Tehran, Iran
Manufacturing Science Workshop | San Antonio, TX
Microbiology | Berlin, Germany
Monoclonal | Rome, Italy
Outsourcing | Barcelona, Spain
Outsourcing/CMO Conference | Washington, DC
Parenteral Packaging | Venice, Italy
PDA/FDA Joint Regulatory Conference | Washington, DC
PDA-PIC/S Training Course on GMPs for APIs | San Juan, Puerto Rico
Universe of Pre-filled Syringes & Injection Devices | Huntington Beach, CA
Visual Inspection | Berlin, Germany
Visual Inspection Interest Group | Washington, DC

Big Data was on the agenda for the 1st PDA Europe Annual Meeting
PDA is known and respected for the scientific and technical contributions it has made to the industry. Sound science is the foundation of PDA’s education, programming and regulatory activities.

The *PDA Journal of Pharmaceutical Science and Technology* has published every year of PDA’s existence, so also celebrated its 70th year. A highlight of 2016 was the addition of a “publish-ahead-of-press” function to the Journal’s website, which allows the editors to post “accepted papers” prior to official publication in a future edition.

Prompted by the 1976 draft FDA guidance on GMPs for large volume parenterals, PDA’s members mobilized and provided technical guidance to the Agency, the U.S. Pharmacopeia and the industry on a number of pressing topics, including container/closures, visual inspection, particulate matter, Limulus Amebocyte Lysate testing, and terminal sterilization. It was this latter topic that became the focus of PDA’s first technical report in 1978 (known as “technical monographs” then): “Validation of Steam Sterilization Cycles.”

By the end of 2016, the library of PDA-owned technical documents produced by member volunteers has grown to nearly 100 technical reports, surveys and points to consider. In a remarkably busy year, PDA published 13 volunteer-driven documents: five technical reports, a points-to-consider document, three surveys, and two books, as well as two papers in the PDA Journal.
In PDA’s Certificate of Incorporation, filed on November 12, 1946 in New York, one of the Association’s primary purposes was to:

“Cultivate and maintain cooperative relations with governmental departments and agencies...and to originate and participate in cooperative enterprises and undertakings with them.”

PDA issued its first comments to a regulatory proposal in 1976 in response to the U.S. FDA request for comment on the proposed “Good Manufacturing Practices for Large Volume Parenterals.” The comments were prepared by the PDA “Research Committee,” reviewed by interested PDA members, and shown to FDA officials, before final submission to the proposed GMP’s docket. The Association has proffered comments on hundreds of regulatory proposals since.

In the forty years since, the process for commenting on regulatory proposals has been formalized:

The Regulatory Affairs and Quality Advisory Board (RAQAB) identifies current regulatory and quality issues affecting the development, manufacturing and quality of healthcare products:

- advises PDA on the impact of such issues
- recommends a plan of action for PDA response
- and develops and makes recommendations to the PDA Board of Directors on association positions

In 2016, PDA’s regulatory participation activities were at the busiest level yet, with 16 comments prepared and submitted throughout the year. Reflecting the growing international influence of PDA, half of the regulatory comments were on proposals issued to regulatory bodies outside the United States. PDA members also commented on a proposal by the U.S. Pharmacopeia’s new General Chapters pilot program.
### Financials

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Revenues</td>
<td>$16,573,562</td>
<td>$15,761,671</td>
</tr>
<tr>
<td>Total Expenses1</td>
<td>$16,161,723</td>
<td>$15,781,884</td>
</tr>
<tr>
<td>Net Income Surplus (Deficit)</td>
<td>$ 411,839</td>
<td>$(20,213)</td>
</tr>
<tr>
<td>Increase (Decrease) in Net Assets</td>
<td>$ 411,839</td>
<td>$(20,213)</td>
</tr>
<tr>
<td>Net Assets at beginning of year</td>
<td>$ 8,343,006</td>
<td>$ 8,363,219</td>
</tr>
<tr>
<td>Net Assets at end of year</td>
<td>$ 8,754,845</td>
<td>$ 8,343,006</td>
</tr>
<tr>
<td>Net Asset ratio (Net Assets/ Annual Expenses)</td>
<td>54%</td>
<td>53%</td>
</tr>
</tbody>
</table>

1 Total expense includes the foreign currency translation adjustment of ($50,745) in 2016 and ($174,442) in 2015. This is considered a non-operating expense item.

#### Revenue

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs &amp; Meetings</td>
<td>$6,288,089</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$3,104,636</td>
</tr>
<tr>
<td>Exhibits &amp; Sponsorships</td>
<td>$2,651,712</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$2,451,987</td>
</tr>
<tr>
<td>Publications</td>
<td>$850,554</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advertising</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$332,665</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$893,919</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$893,919</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>$16,573,562</td>
<td>$15,761,671</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Expenses</td>
<td>$16,161,723</td>
<td>$15,781,884</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Income Surplus (Deficit)</td>
<td>$ 411,839</td>
<td>$(20,213)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase (Decrease) in Net Assets</td>
<td>$ 411,839</td>
<td>$(20,213)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Assets at beginning of year</td>
<td>$ 8,343,006</td>
<td>$ 8,363,219</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Assets at end of year</td>
<td>$ 8,754,845</td>
<td>$ 8,343,006</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Asset ratio (Net Assets/ Annual Expenses)</td>
<td>54%</td>
<td>53%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Cash & Investments

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td></td>
</tr>
<tr>
<td>2011</td>
<td></td>
</tr>
<tr>
<td>2012</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
</tr>
</tbody>
</table>
From humble beginnings in 1991, the PDA/FDA Joint Regulatory has become PDA’s consistently largest signature meeting and a truly must-attend event for pharmaceutical/biopharmaceutical manufacturing community around the world.

PDA/FDA JOINT REGULATORY CONFERENCE

25TH ANNIVERSARY
1991-2016
The 1962 PDA Annual Meeting Banquet